Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Database
Journal subject
Affiliation country
Publication year range
1.
Regul Pept ; 136(1-3): 92-7, 2006 Sep 11.
Article in English | MEDLINE | ID: mdl-16822558

ABSTRACT

We investigated the expression and localization of B1 receptor in tissues of rats submitted to a renin-dependent model of hypertension (2K-1C), and analyzed the influence of endogenous Ang II in modulating the in vivo expression of these receptors. B1 mRNA levels in the heart, kidney and thoracic aorta were quantified by real time PCR, B1 receptor protein expression was assessed by immunohistochemistry, plasma Ang II levels were analyzed by radioimmunoassay and the effects of AT1 receptor blockade were determined after losartan treatment. 2K-1C rats presented a marked increase in Ang II levels when compared to sham-operated rats. In parallel, cardiac- (but not renal and aortic) B1 mRNA levels were 15-fold higher in 2K-1C than in sham rats. In 2K-1C, B1 expression was detected in the endothelium of small cardiac arteries and in cardiomyocytes. Losartan completely reverted the increased B1 mRNA levels and significantly decreased the protein expression observed in 2K-1C rats, despite reducing, but not normalizing blood pressure. We conclude that in the 2K-1C rat, induction of cardiac B1 receptor might be tightly linked to AT1 receptor activation. These data suggest the existence of a new site of interaction between kinins and angiotensins, and might provide important contributions for a better understanding of the pathophysiology of hypertension.


Subject(s)
Angiotensin II/metabolism , Gene Expression Regulation , Kinins/biosynthesis , Angiotensin II/blood , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Hypertension/pathology , Kidney/metabolism , Losartan/pharmacology , Male , RNA, Messenger/metabolism , Rats , Rats, Inbred SHR , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Time Factors
2.
Arq Bras Endocrinol Metabol ; 50(2): 304-12, 2006 Apr.
Article in Portuguese | MEDLINE | ID: mdl-16767296

ABSTRACT

Endothelial dysfunction is associated with several vascular conditions as atherosclerosis, hypertension, hyperlipidemia and diabetes mellitus. In all these conditions insulin resistance (IR) is present. Cytokines are low molecular weight proteins with several endocrine and metabolic functions that participate of inflammation and immune response. Several of these cytokines are independent risk factors for cerebrovascular and coronary artery disease. The major sources of cytokines (adipokines) are the visceral and subcutaneous adipose tissues. Thus, increased adipose tissue mass is associated with alteration in adipokine production as over expression of tumor necrosis factor alpha, interleukin 6, plasminogen activator inhibitor 1, and under expression of adiponectin in adipocite tissue. The pro-inflammatory status associated with these changes provides a potential link between IR and endothelial dysfunction, the early stage in the atherosclerotic process, in obese individuals, and type 2 diabetic patients. Reduction of adipose tissue mass through weight reduction in association with exercise reduces TNF-alpha, IL-6, and PAI-1, increases adiponectin, and is associated with improved insulin sensitivity and endothelial function. This review will focus on the evidence for regulation of endothelial function by insulin and the adypokines such as adyponectin, leptin, resistin, IL-6 and TNF-alpha. Interaction between insulin signaling and adypokines will be discussed, as well as the concept that aberrant adypokine secretion in IR and/or obesity impairs endothelial function and contributes further to reduce insulin sensitivity.


Subject(s)
Cardiovascular Diseases/etiology , Cytokines/physiology , Endothelium, Vascular/physiopathology , Insulin Resistance/physiology , Adiponectin/physiology , Fatty Acids/physiology , Humans , Hypertension/complications , Inflammation/metabolism , Leptin/physiology
3.
Regul Pept ; 127(1-3): 183-9, 2005 Apr 15.
Article in English | MEDLINE | ID: mdl-15680485

ABSTRACT

The present study determined the participation of PGI2 in the angiotensin-(1-7) [Ang-(1-7)]/bradykinin (BK) interaction, in the presence and absence of Angiotensin Converting Enzyme (ACE) inhibition, trying to correlate it with tissue levels of both peptides. The isolated mesenteric arteriolar bed of Spontaneously Hypertensive Rats (SHR) was perfused with Krebs or Krebs plus enalaprilat (10 nM), and drugs were injected alone or in association. BK (10 ng)-induced relaxation was potentiated by Ang-(1-7) (2.2 microg) in the presence or absence of enalaprilat. Ang-(1-7) receptor blockade [A-779 (4.8 microg)] did not interfere with the BK effect in preparations perfused with normal Krebs, but reversed the increased BK relaxation observed after ACE inhibition. PGI2 release by mesenteric vessels was not altered by BK or Ang-(1-7) alone, but was increased when both peptides were injected in association, in the absence or in the presence of enalaprilat. ACE inhibition caused a 2-fold increase in the BK tissue levels, and a significant decrease in the Ang-(1-7) values. We conclude that endogenous Ang-(1-7) has an important contribution to the effect of ACE inhibitors participating in the enhancement of BK response. The mechanism of Ang-(1-7) potentiating effect probably involves an increased production of PGI2. Our results suggest that a different enzymatic pathway (non-related to ACE) is involved in the local Ang-(1-7) metabolism.


Subject(s)
Angiotensin I/metabolism , Angiotensin-Converting Enzyme Inhibitors/metabolism , Antihypertensive Agents/metabolism , Arterioles/metabolism , Blood Pressure/physiology , Bradykinin/metabolism , Epoprostenol/metabolism , Peptide Fragments/metabolism , Animals , Enalaprilat/metabolism , Male , Mesentery/blood supply , Rats , Rats, Inbred SHR
4.
Life Sci ; 121: 78-87, 2015 Jan 15.
Article in English | MEDLINE | ID: mdl-25497710

ABSTRACT

AIMS: Studies have associated obesity with a wide variety of cancers. Metformin, an anti-diabetic drug, has recently received attention as a potentially useful therapeutic agent for treating cancer. Therefore, the objective of this study was to analyze the mechanisms involved in the increase in tumor development and the reduction of it by metformin in obesity using an experimental breast tumor model. MATERIAL AND METHODS: Newborn male Wistar rats were subcutaneously injected with 400mg/kg monosodium glutamate (MSG) (obese) or saline (control) at 2, 3, 4, 5 and 6 days of age. After 16 weeks, 1 × 10(7) Walker-256 tumor cells were subcutaneously injected in the right flank of the rats and concomitantly the treatment with metformin 300 mg/kg/15 days, via gavage, started. The rats were divided into 4 groups: control tumor (CT), control tumor metformin (CTM), obese-MSG tumor (OT) and obese-MSG tumor metformin (OTM). On the 18th week the tumor development and metformin effect were analyzed. KEY FINDINGS: Tumor development was higher in OT rats compared with CT rats. Activation of insulin-IR-ERK1/2 pathway and an anti-apoptotic effect might be the mechanisms involved in the higher development of tumor in obesity. The effect of metformin reducing the tumor development in obese rats might involve increased mRNA expression of pRb and p27, increased activity of AMPK and FOXO3a and decreased expression of p-ERK1/2 (Thr202/Tyr204) in Walker-256 tumor. SIGNIFICANCE: Our data allow us to suggest that metformin, reducing the stimulatory effect of obesity on tumor development, has a potential role in the management of cancers.


Subject(s)
Carcinoma 256, Walker/drug therapy , Cyclic AMP-Dependent Protein Kinases/metabolism , Food Additives , Forkhead Transcription Factors/metabolism , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Obesity/complications , Sodium Glutamate , Animals , Carcinoma 256, Walker/pathology , Female , Forkhead Box Protein O3 , Male , Mammary Neoplasms, Experimental/drug therapy , Mammary Neoplasms, Experimental/metabolism , Mammary Neoplasms, Experimental/pathology , Obesity/chemically induced , Obesity/pathology , Rats , Rats, Wistar , Signal Transduction/drug effects
5.
J Vasc Res ; 43(5): 401-10, 2006.
Article in English | MEDLINE | ID: mdl-16877872

ABSTRACT

Overproduction of vasoconstrictor prostanoids and reduced prostacyclin levels have been related to the male diabetic-linked vascular dysfunction. However, it is not clear yet if these changes also occur in diabetic females. The aim of this study was to verify the role of prostanoids in the vascular dysfunction of diabetic female rats. The parameters studied were the mesenteric arteriolar reactivity (intravital microscopy and isolated perfused arteriolar bed), prostanoid measurement (enzyme immunoassay), superoxide generation (intravital fluorescence microscopy), and the presence of peroxynitrite (Western blot for nitrotyrosine-containing proteins). The response to acetylcholine was decreased in arterioles of diabetic female rats and diclofenac, but not ridogrel, corrected the altered response. The unstimulated (basal) release of thromboxane B2 (TXB2), but not prostaglandin F2alpha (PGF2alpha) or 6-keto-PGF1alpha, was increased in the mesenteric perfusate from diabetic female rats. Increased production of PGF2alpha and 6-keto-PGF1alpha, but not TXB2, was induced by acetylcholine in diabetic arterioles. The superoxide generation was increased in diabetic female rats and diclofenac corrected it. Diabetes increased nitrotyrosine-containing proteins in mesenteric microvessels. In conclusion, our data show that the increase of constrictor prostanoid release, most likely PGF2alpha, could be involved in the reduced endothelium-dependent vasodilation of diabetic female rats. In addition, the enhanced activation of cyclooxygenase may be a source of superoxide anion generation in this model.


Subject(s)
Cyclooxygenase Inhibitors/pharmacology , Diabetes Mellitus, Experimental/physiopathology , Endothelium, Vascular/physiopathology , Nitric Oxide/physiology , Prostaglandins/physiology , Vasodilation/physiology , Acetylcholine/pharmacology , Animals , Arterioles/physiopathology , Bradykinin/pharmacology , Endothelium, Vascular/drug effects , Female , Histamine/pharmacology , Mesenteric Arteries/physiopathology , Rats , Rats, Wistar , Superoxides/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL